טוען...
One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study
OBJECTIVE: To assess efficacy and tolerability of 1-year erenumab treatment in patients with episodic migraine. METHODS: Patients were randomized (n = 955; 1:1:1) during the 24-week double-blind treatment phase (DBTP) to monthly subcutaneous placebo or erenumab 70 or 140 mg. At week 24, 845 patients...
שמור ב:
| הוצא לאור ב: | Neurology |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Lippincott Williams & Wilkins
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7455346/ https://ncbi.nlm.nih.gov/pubmed/32636324 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000010019 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|